-
Product Insights
NewNet Present Value Model: Rocket Pharmaceuticals Inc’s RPA-601
Empower your strategies with our Net Present Value Model: Rocket Pharmaceuticals Inc's RPA-601 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Rocket Pharmaceuticals Inc’s RPA-501
Empower your strategies with our Net Present Value Model: Rocket Pharmaceuticals Inc's RPA-501 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
AntWorks Pte. Ltd. Partner Ecosystem Profile
GlobalData's new report titled "AntWorks Pte. Ltd. Partner Ecosystem Profile " serves as a crucial resource for analyzing the partner landscape of AntWorks Pte. Ltd.. It identifies the company's partners across various countries and regions, and tracks over 70 data fields including IT solution areas of interest, business fundamental data (such as revenue and employee bands), partner engagement signing country, focused verticals, and more.It is based on data and information gathered from a range of sources including company websites, press...
-
Product Insights
Kryon Systems Ltd Partner Ecosystem Profile
GlobalData's new report titled "Kryon Systems Ltd Partner Ecosystem Profile " serves as a crucial resource for analyzing the partner landscape of Kryon Systems Ltd. It identifies the company's partners across various countries and regions, and tracks over 70 data fields including IT solution areas of interest, business fundamental data (such as revenue and employee bands), partner engagement signing country, focused verticals, and more.It is based on data and information gathered from a range of sources including company websites, press...
-
Product Insights
NewNet Present Value Model: Rocket Pharmaceuticals Inc’s RPA-501
Empower your strategies with our Net Present Value Model: Rocket Pharmaceuticals Inc's RPA-501 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Consumer Insights
Kenya Enterprise ICT Investment Market Trends by Budget Allocations, Future Outlook, Key Business Areas and Challenges
Kenya Enterprise ICT Investment Market Overview According to GlobalData’s Kenya Enterprise ICT Investment Trends Report 2023, most of the enterprises from the country have increased their ICT budget for 2023 with more than 84% of respondents from our recent survey claiming the same. In contrast, a relatively low proportion of enterprises have trimmed their ICT budget for 2023 compared to previous year. Buy the Full Report to Gain More Insights on Enterprise ICT Investment Trends in Kenya Download a Free...
-
Consumer Insights
Nigeria Enterprise ICT Investment Market Trends by Budget Allocations, Future Outlook, Key Business Areas and Challenges
Nigeria Enterprise ICT Investment Market Overview According to GlobalData’s Nigeria Enterprise ICT Investment Trends Report 2023, most of the enterprises from the country have increased their ICT budget for 2023 with more than 94% of respondents from our recent survey claiming the same. In contrast, a relatively low proportion of enterprises have trimmed their ICT budget for 2023 compared to previous year. Buy the Full Report to Gain More Insights on Enterprise ICT Investment Trends in Nigeria Download a Free...
-
Company Insights
Innovation and Patenting activity of RPA Holdings Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of RPA Holdings Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RPA-601 in Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RPA-601 in Cardiomyopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RPA-601 in Cardiomyopathy Drug Details: RPA-601 is under development for the treatment of PKP2-associated...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RPA-501 in Glycogen Storage Disorders (GSD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RPA-501 in Glycogen Storage Disorders (GSD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RPA-501 in Glycogen Storage Disorders (GSD) Drug Details: RPA-501 is under...